Intuitive Surgical, Inc. vs GeneDx Holdings Corp — how do they compare? Intuitive Surgical, Inc. trades at $401.3 (market cap $141.75B), while GeneDx Holdings Corp trades at $81.32 (market cap $2.44B). The key difference: Intuitive Surgical, Inc. is far larger — about 58.1× GeneDx Holdings Corp's market cap. Which is the better fit depends on your goals.
| ISRG | WGS | |
|---|---|---|
Market Cap | $141.75B | $2.44B |
Sector | Health | Technology |
52-Week High | $592.85 | $167.51 |
52-Week Low | $332.02 | $34.51 |
Enterprise Value | $136.53B | $2.48B |
Signals from Pluang's Aura AI — not financial advice
Intuitive Surgical (ISRG) trades at $401.46, up 2.05% today, with strong quarterly earnings beats and bullish analyst consensus. The stock shows robust revenue growth, expanding margins, and solid cash flow, supported by the da Vinci 5 system adoption. Technical indicators are mixed, with RSI signaling overbought conditions but moving averages bullish.
Outlook remains positive due to durable demand and innovation, though high valuation and competition pose risks. Upside to the $518.10 consensus target offers potential, but investors should weigh premium multiples against growth sustainability.
GeneDx Holdings Corp (WGS) trades at $82.39, up 5.79% in the past 24 hours, with a bullish technical signal and strong analyst support. The company reported Q2 2026 revenue of $114.4 million, beating guidance, and returned to adjusted profitability earlier than expected. However, net income remains negative at -$106 million for 2026, and the stock faces class action lawsuits with an August 3, 2026 deadline.
Outlook is mixed: bullish technicals and analyst consensus suggest upside to the $90 price target, but fundamental weaknesses and legal risks pose significant challenges. Investment opportunity hinges on sustained revenue growth and margin improvement, while risks include profitability pressures and litigation outcomes.
Trailing returns across standard periods
Latest headlines on both assets
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →